Deciphera Pharmaceuticals, Inc., known for creating transformative cancer treatments, has entered a definitive acquisition agreement with Japan’s ONO Pharmaceutical Co., Ltd. The deal, valued at $25.60 per share, represents a total equity value of $2.4 billion in cash. Goodwin’s M&A and Life Sciences teams, led by Stuart Cable, acted as advisors for Deciphera in this transaction. The biopharmaceutical company, listed on NASDAQ under DCPH, is utilizing its proprietary switch-control kinase inhibitor platform to develop a comprehensive portfolio of medicines, including products for the treatment of fourth-line GIST, with its leading drug QINLOCK approved across various global markets. The extensive Goodwin team encompassed professionals across several functions, manifesting the complexity and significance of the deal in the oncology pharmaceutical sector.

Pharmaceuticals, Legal Services, Healthcare,Global, Japan, United States